Therapeutic inhibitors of tumor necrosis factor in Crohn's disease.
Therapeutic options for patients with refractory ulcerative colitis or Crohn's disease have recently been augmented by the introduction of biological therapies. The pro-inflammatory cytokine, tumor necrosis factor (TNF)-alpha is present in elevated concentrations in patients with inflammatory bowel disease and inhibitors of TNF alpha have proved effective as treatment. Strategies aimed at reducing TNF in patients with Crohn's disease, include the mouse/human chimeric monoclonal antibody, infliximab (Centocor Inc), the humanized monoclonal antibody, CDP-571 (Celltech Group plc), the human recombinant TNF receptor fusion protein, etanercept (Immunex Corp), and thalidomide. New approaches, including the use of soluble TNF receptors, appear promising. This article reviews the evidence of therapeutic inhibition of TNF.
Ganesan
Srinivasan
S
Phase 1 Clinical Trials Unit, 119 Looseleigh Lane, Derriford, Plymouth, PL6 5HH, UK.
Travis
Simon P L
SP
Ahmad
Tariq
T
Jazrawi
Riadh
R
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D014409:Tumor Necrosis Factor-alpha